$OLMA News
Last published 1d ago
- 1d agoOLMAOlema Pharmaceuticals, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoOLMAOlema Oncology Reports Third Quarter 2026 Financial and Operating ResultsGlobeNewswireSAN FRANCISCO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the third quarter ended September 30, 2026.
- 1w agoOLMAOlema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer SymposiumGlobeNewswireSAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery,
- 1w agoOLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery,
- 1w agoOLMAOlema Oncology to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery,
- 1mo agoOLMAOlema Oncology - 1773715 - OLEMA PHARMACEUTICALS INCEarnings Call TranscriptsThank you all for coming today and coming to the Morgan Stanley Healthcare Conference. My name is Ruck Byun. I'm head of West Coast Healthcare Investment Banking for Morgan Stanley. I have the pleasure of hosting Sean Bo
- 1mo agoOLMAMorgan Stanley 24th Annual Global Healthcare Conference - OLEMA PHARMACEUTICALS INCEarnings Call TranscriptsThank you all for coming today and coming to the Morgan Stanley Healthcare Conference. My name is Ruck Byun. I'm head of West Coast Healthcare Investment Banking for Morgan Stanley. I have the pleasure of hosting Sean Bo
- 2mo agoOLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery,
- 2mo agoOLMAOlema Oncology to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery,
- 3mo agoOLMAOlema Oncology Appoints Jason O’Byrne as Chief Financial OfficerGlobeNewswireSAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery,
- 3mo agoOLMAOlema Oncology Reports Second Quarter 2026 Financial and Operating ResultsGlobeNewswireCompleted enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO Annual MeetingAnnounced a
- 3mo agoOLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery,
- 4mo agoOLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, July 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery,
- 5mo agoOLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 5mo agoLLYNTHIOLMAPFELilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to ExplodeGlobeNewswireDENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo
- 5mo agoOLMAOlema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate CancerGlobeNewswireStudy to evaluate OP-3136, Olema's novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026First clinical collaboration for OP-3136; results to inform
- 5mo agoOLMAOlema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual MeetingGlobeNewswireOP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse eventsOP-3136 shows evidence of anti-tumor activity across multiple solid tumor
- 5mo agoOLMAOlema Oncology to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 6mo agoOLMAOlema Oncology Reports First Quarter 2026 Financial and Operating ResultsGlobeNewswireTop-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patientsFirst clinical data from OP-3136 Phase 1 study to be presented at ASCO Ended the first quarter with
- 6mo agoOLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 6mo agoOLMAOlema Oncology Appoints Prakash Raman, Ph.D., to Board of DirectorsGlobeNewswireSAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 6mo agoOLMAOlema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual MeetingGlobeNewswireSAN FRANCISCO, April 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 6mo agoOLMAOlema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual MeetingGlobeNewswirePalazestrant's mechanism of action confirmed; full recruitment of corepressor protein NCoR1 enables complete antagonism of the estrogen receptorOP-3136, in combination with palazestrant, exhibits synergistic anti-tumor
- 7mo agoOLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, April 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 8mo agoOLMAOlema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsGlobeNewswireOn-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancerAdvanced enrollment in the OPERA-02
- 8mo agoOLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 8mo agoOLMAOlema Oncology to Present at the TD Cowen 46th Annual Health Care ConferenceGlobeNewswireSAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 9mo agoOLMAOlema Oncology to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 9mo agoOLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 9mo agoOLMAOlema Oncology Announces Departure of Chief Operating and Financial OfficerGlobeNewswireSAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 10mo agoOLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 10mo agoOLMAOlema Oncology to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 11mo agoOLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 11mo agoOLMAOlema Oncology to Participate in 8th Annual Evercore Healthcare ConferenceGlobeNewswireSAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 11mo agoOLMAOlema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireSAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 11mo agoOLMAOlema Oncology Announces Pricing of $190.0 Million Public Offering of Common StockGlobeNewswireSAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 11mo agoOLMAOlema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireSAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 1y agoOLMAOlema Oncology Reports Third Quarter 2025 Financial and Operating ResultsGlobeNewswireAnnounced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancerInitiated OPERA-02 Phase 3 trial of palazestrant in combination with
- 1y agoOLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 1y agoOLMAOlema Oncology to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 1y agoOLMAOlema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025GlobeNewswireSAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 1y agoOLMAShares of breast cancer therapy developer Olema Pharmaceutical could more than double from hereCNBCThe clinical-stage biopharma stock has rallied more than 70% over the past three months on the back of promising clinical data for its lead drug, Palazestrant.
- 1y agoOLMAOlema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025GlobeNewswirePalazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patientsIn the 120 mg
- 1y agoOLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 1y agoOLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 1y agoOLMAPFEOlema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast CancerGlobeNewswireStudy to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in frontline
- 1y agoOLMAOlema Oncology to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
- 1y agoONCYPRPHIOBTOLMA+1Biotech Stocks Rally as Oncology Market Targets $866B by 2034PR NewswireEquity Insider News Commentary – Despite alarming federal budget cuts that stand to potentially harm the national battle against cancer, it appears...
- 1y agoOLMAOlema Oncology Reports Second Quarter 2025 Financial and Operating ResultsGlobeNewswireSelected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclibOPERA-01 enrollment ongoing with top-line data expected in the
- 1y agoOLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and